This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Messerli, F. H. Search for Related Content PubMed PubMed Citation Articles by Messerli, F. H.

VIEWPOINT

Doxazosin and congestive heart failure

^a Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA

Manuscript received June 7, 2001; revised manuscript received July 12, 2001, accepted August 1, 2001.

^* Reprint requests and correspondence: Dr. Franz H. Messerli, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, LA 70121 USA
fmesserli{at}aol.com

Congestive heart failure (CHF) is the most devastating cardiac sequella of long-standing hypertension. Recent data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have shown the risk of CHF to be twice as high with doxazosin than with chlorthalidone. Although some questions remain regarding the diagnosis and mortality of CHF in the doxazosin arm and regarding the risk of dying from malignancy in the diuretic arm of ALLHAT, drugs used to treat hypertension should lower the CHF risk. Therefore, until ironclad safety data are provided, doxazosin, and probably all alpha-blockers, should no longer be used as first-line antihypertensive therapy.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ALLHAT = Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial   CHF = congestive heart failure

This article has been cited by other articles:

				B. R. Davis, J. B. Kostis, L. M. Simpson, H. R. Black, W. C. Cushman, P. T. Einhorn, M. A. Farber, C. E. Ford, D. Levy, B. M. Massie, et al. Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Circulation, November 25, 2008; 118(22): 2259 - 2267. [Abstract] [Full Text] [PDF]

				R. S. Stafford, C. D. Furberg, S. N. Finkelstein, I. M. Cockburn, T. Alehegn, and J. Ma Impact of Clinical Trial Results on National Trends in {alpha}-Blocker Prescribing, 1996-2002 JAMA, January 7, 2004; 291(1): 54 - 62. [Abstract] [Full Text] [PDF]

				Diuretic Versus {alpha}-Blocker as First-Step Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension, September 1, 2003; 42(3): 239 - 246. [Abstract] [Full Text] [PDF]